Acino

Acino operates as a speciality pharmaceutical company with a deliberate focus on emerging and underserved markets, channelling its commercial and manufacturing capabilities into regions including Africa, Latin America, the Middle East, Turkiye, North Africa, Ukraine, and the broader Eurasian corridor. This geographic strategy positions the Swiss-headquartered group where established multinationals have historically had thinner reach.

The company's operational model spans three integrated pillars: partnering arrangements with third-party rights holders, in-house manufacturing supported by dedicated manufacturing sites, and direct product marketing. Quality assurance and supplier governance are identified as components of the manufacturing framework, reflecting the compliance requirements that apply across international markets.

Acino's therapeutic portfolio addresses conditions prevalent in the markets it serves. Disease areas covered include cardiovascular disease, hypertension, infectious diseases, acid reflux, Helicobacter pylori infection, colorectal cancer, and narcolepsy. The company also maintains patient-facing health information on these conditions, indicating a level of engagement beyond the purely commercial. Counterfeit medicines awareness is included among its health matter communications, a consideration of particular relevance in markets with complex distribution environments.

Sustainability forms part of the company's published agenda, alongside career development and media engagement, suggesting an organisation structured for long-term presence in its chosen regions rather than opportunistic market entry.

Further information is available at acino.swiss.